Note: Descriptions are shown in the official language in which they were submitted.
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
IL-8 RECEPTOR ANTAGONISTS
FIELD OF THE INVENTION
This invention relates to a novel group of cyclicguanidine compounds,
processes for the preparation thereof, the use thereof in treating IL-8,
GROoc, GRO[3,
GRO~y. NAP-2, and ENA-78 mediated diseases and pharmaceutical compositions for
use in such therapy.
BACKGROUND OF THE INVENTION
Many different names have been applied to Interleukin-8 (IL-8), such as
neutrophil attractant/activation protein-1 (NAP-1), monocyte derived
neutrophil
chemotactic factor (MDNCF), neutrophil activating factor (NAF), and T-cell
lymphocyte chemotactic factor. Interleukin-8 is a chemoattractant for
neutrophils,
basophils, and a subset of T-cells. It is produced by a majority of nucleated
cells
including macrophages, fibroblasts, endothelial and epithelial cells exposed
to TNF,
IL-la, IL-1(3 or LPS, and by neutrophils themselves when exposed to LPS or
chemotactic factors such as FMLP. M. Baggiolini et al, J. Clin. Invest. 84,
1045
( 1989); J. Schroder et al, J. Immunol. 139, 3474 ( 1987) and J. Immunol. 144,
2223
(1990) ; Strieter, et al, Science 243, 1467 (1989) and J. Biol. Chem. 264,
10621
(1989); Cassatella et al, J. Immunol. 148, 3216 (1992).
Groa., GROG, GROy and NAP-2 also belong to the chemokine oc family.
Like IL-8 these chemokines have also been referred to by different names. For
instance GROa, (3, 'y have been referred to as MGSAa,, ~3 and 'y respectively
(Melanoma Growth Stimulating Activity), see Richmond et al, J. Cell Physiology
129, 375 ( 1986) and Chang et al, J. Immunol 148, 451 ( 1992). All of the
chemokines
of the a-family which possess the ELR motif directly preceding the CXC motif
bind
to the IL-8 B receptor.
IL-8, Groa, GR0~3, GRO~y, NAP-2 and ENA-78 stimulate a number of
functions in vitro. They have all been shown to have chemoattractant
properties for
3o neutrophils, while IL-8 and GROa have demonstrated T-lymphocytes, and
-1-
CA 02374295 2001-11-27
WO 00/72840 PCT/L1S00/14660
basophiles chemotactic activity. In addition IL-8 can induce histamine release
from
basophils from both normal and atopic individuals. GRO-a and IL-8 can in
addition,
induce lysozomal enzyme release and respiratory burst from neutrophils. IL-8
has
also been shown to increase the surface expression of Mac-1 (CDllb/CD18) on
neutrophils without de novo protein synthesis. This may contribute to
increased
adhesion of the neutrophils to vascular endothelial cells. Many known diseases
are
characterized by massive neutrophil infiltration. As IL-8, Grooc, GR0~3, GROy
and
NAP-2 promote the accumulation and activation of neutrophils, these chemokines
have been implicated in a wide range of acute and chronic inflammatory
disorders
including psoriasis and rheumatoid arthritis, Baggiolini et al, FEBS Lett.
307, 97
( 1992); Miller et al, Crit. Rev. Immunol. 12, 17 ( 1992); Oppenheim et al,
Annu.
Rev. Immunol. 9, 617 ( 1991 ); Seitz et al., J. Clin. Invest. 87, 463 ( 1991
); Miller et
al., Am. Rev. Respir. Dis. 146, 427 (1992); Donnely et al., Lancet 341, 643
(1993).
In addition the ELR chemokines (those containing the amino acids ELR motif
just
prior to the CXC motif) have also been implicated in angiostasis, Strieter et
al,
Science 258, 1798 (1992).
In vitro, IL-8, Grooc, GROG, GROy, and NAP-2 induce neutrophil shape
change, chemotaxis, granule release, and respiratory burst, by binding to and
activating receptors of the seven-transmembrane, G-protein-linked family, in
particular by binding to IL-8 receptors, most notably the B-receptor, Thomas
et al.,
J. Biol. Chem. 266, 14839 ( 1991 ); and Holmes et al., Science 253, 1278 (
1991 ). The
development of non-peptide small molecule antagonists for members of this
receptor
family has precedent. For a review see R. Freidinger in: Progress in Drug
Research,
Vol. 40, pp. 33-98, Birkhauser Verlag, Basel 1993. Hence, the IL-8 receptor
represents a promising target for the development of novel anti-inflammatory
agents.
Two high affinity human IL-8 receptors (77°Io homology) have been
characterized: IL-8Ra, which binds only IL-8 with high affinity, and IL-8RB,
which
has high affinity for IL-8 as well as for GRO-a, GROG, GROy and NAP-2. See
Holmes et al., supra; Murphy et al., Science 253, 1280 (1991); Lee et al., J.
Biol.
-2-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
Chem. 267, 16283 (1992); LaRosa et al., J. Biol. Chem. 267, 25402 (1992); and
Gayle et al., J. Biol. Chem. 268, 7283 (1993).
There remains a need for treatment, in this field, for compounds which are
capable of binding to the IL-8 a or ~3 receptor. Therefore, conditions
associated with
an increase in IL-8 production (which is responsible for chemotaxis of
neutrophil
and T-cells subsets into the inflammatory site) would benefit by compounds
which
are inhibitors of IL-8 receptor binding.
SUMMARY OF THE INVENTION
This invention provides for a method of treating a chemokine mediated
1o disease, wherein the chemokine is one which binds to an IL-8 a or (3
receptor and
which method comprises administering an effective amount of a compound of
Formula (I) or a pharmaceutically acceptable salt thereof. In particular the
chemokine is IL-8.
This invention also relates to a method of inhibiting the binding of IL-8 to
its
15 receptors in a mammal in need thereof which comprises administering to said
mammal an effective amount of a compound of Formula (I).
Compounds of Formula (I) useful in the present invention are represented by
the structure:
(R~)m
R
I (R2)
N~N
H
(l~n
(I)
wherein:
R is OH, SH, NHS02Rd~
Rd is NR6R7, alkyl, arylCl-4alkyl, arylC 2_4 alkenyl, heteroaryl,
hetroaryl-C 1 _4alkyl, heteroarylC2-4 alkenyl, heterocyclic, heterocyclicC 1-4
-3-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
alkyl, wherein the aryl, heteoaryl and heterocyclic rings may all be
optionally
substituted;
R( and R~ are independently hydrogen, or a C 1 _4 alkyl group, or R6 and R~
together
with the nitrogen to which they are attached form a 5 to 7 member ring which
ring
may optionally contain an additional heteroatom is selected from oxygen,
nitrogen
or sulfur, and which ring may be optionally substituted;
R 1 is independently selected from hydrogen, halogen, nitro, cyano,
halosubstituted
Cl-10 alkyl, C1-10 alkyl, C2-10 alkenyl, C1-10 alkoxy, halosubstituted C1-10
alkoxy, azide, (CRgRg)q S(O)tR4, hydroxy, hydroxy Cl_4alkyl, aryl, aryl C1-4
to alkyl, aryloxy, aryl C1_4 alkyloxy, heteroaryl, heteroarylalkyl,
heterocyclic,
heterocyclic C 1 _4alkyl, heteroaryl C 1 _4 alkyloxy, aryl C2-10 alkenyl,
heteroaryl
C2-10 alkenyl, heterocyclic C2_10 alkenyl, (CRgRg)qNR4R5, C2_10 alkenyl
C(O)NR4R5, (CRgRg)q C(O)NR4R5, (CRgRg)q C(O)NR4R10, S(O)3H,
S(O)3Rg, (CRgRg)q C(O)R11, C2-10 alkenyl C(O)R11, C2-10 alkenyl
15 C(O)OR11(CRgRg)q C(O)OR12, (CRgRg)q OC(O) R11,
(CRgRg)qNRq.C(O)R11, (CRgRg)q NHS(O)2R1~, (CRgRg)q S(O)2NR4R5, or
two R1 moieties together may form O-(CH2)s0- or a 5 to 6 membered
unsaturated ring;
q is 0, or an integer having a value of 1 to 10;
2o t is 0, or an integer having a value of 1 or 2;
s is an integer having a value of 1 to 3;
R4 and RS are independently hydrogen, optionally substituted C 1 _4 alkyl,
optionally
substituted aryl, optionally substituted aryl C 1 _4alkyl, optionally
substituted
heteroaryl, optionally substituted heteroaryl C 1 _4alkyl, heterocyclic,
25 heterocyclicC 1 _4 alkyl, or R4 and RS together with the nitrogen to which
they
are attached form a 5 to 7 member ring which may optionally comprise an
additional heteroatom selected from oxygen, nitrogen or sulfur;
R2 is independently selected from C2_Salkyl and C2_Salkenyl all of which
moieties may
be optionally substituted one to three times independently by halogen; nitro;
-4-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
halosubstituted C 1 _4 alkyl; C 1 _4 alkyl; amino, mono or di-C 1 _4 alkyl
substituted
amine; hydroxy; Cl_4 alkoxy; NR9C(O)Ra; S(O)m Ra; C(O)NR(R~; C(O)OH;
C(O)ORa; S(O)2NR(R~; NHS(O)2Ra; and optionally containing, in addition to
carbon, independently, 1 to 3 NR9, O, C(O), S, SO, or S02 moities;
Y is independently selected from hydrogen; halogen; nitro; cyano;
halosubstituted
Cl-10 alkyl; Cl-10 alkyl; C2_10 alkenyl; Cl-10 alkoxy; halosubstituted Cl-10
alkoxy; azide; (CRgRg)q S(O)tRq.; hydroxy; hydroxyCl_4alkyl; aryl; aryl Cl-4
alkyl; aryloxy; arylC 1 _4 alkyloxy; heteroaryl; heteroarylalkyl; heteroaryl C
1-4
alkyloxy; heterocyclic, heterocyclic C 1 _4alkyl; aryl C2_ l p alkenyl;
heteroaryl
1o C2-10 alkenyl; heterocyclic C2_10 alkenyl; (CRgRg)q NR4R5; C2_10 alkenyl
C(O)NR4R5; (CRgRg)q C(O)NR4R5; (CRgRg)q C(O)NR4R10; S(O)3H;
S(O)3Rg; (CRgRg)q C(O)Rl l; C2-10 alkenyl C(O)Rl l; C2-10 alkenyl
C(O)ORlI; C(O)Rl l; (CRgRg)q C(O)OR12; (CRgRg)q OC(O) Rl l; (CRgRg)q
NR4C(O)Rl l, (CRgRg)q NHS(O)ZRd, (CRgRg)q S(O)2NRq.RS; or two Y
15 moieties together may form O-(CH2)s0- or a 5 to 6 membered unsaturated
ring;
n is an integer having a value of 1 to 3;
m is an integer having a value of 1 to 3;
Rg is hydrogen or C 1 _4 alkyl;
R9 is hydrogen or Cl-4alkyl;
2o Rlp is Cl_10 alkyl C(O)2Rg;
R 11 is hydrogen, C 1 _4 alkyl, optionally substituted aryl, optionally
substituted aryl
C 1 _4alkyl, optionally substituted heteroaryl, optionally substituted
heteroarylCl_4alkyl, optionally substituted heterocyclic, or optionally
substituted
heterocyclicC 1 _4alkyl;
25 R12 is hydrogen, Cl_10 alkyl, optionally substituted aryl or optionally
substituted
arylalkyl;
-5-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
R 1 ~ is C 1 _4alkyl, aryl, arylalkyl, heteroaryl, heteroarylC 1-4alkyl,
heterocyclic, or
heterocyclicC 1 _4alkyl, wherein the aryl, heteroaryl and heterocyclic rings
may
all be optionally substituted; and
Ra is an alkyl, aryl, arylC1-4alkyl, heteroaryl, heteroaryl C1-4alkyl,
heterocyclic, or
a heterocyclic C 1-4alkyl moiety, all of which moieties may be optionally
substituted.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of Formula (I) may also be used in association with the
veterinary treatment of mammals, other than humans, in need of inhibition of
IL-8 or
to other chemokines which bind to the IL-8RA and RB receptors. Chemokine
mediated diseases for treatment, therapeutically or prophylactically, in
animals
include disease states such as those noted herein in the Methods of Treatment
section.
Exemplified compounds of Formula (I) include:
4-[[1-(2-bromophenyl)-4,5-dihydro-5-oxo-1H-imidazol-2-yl]amino]-3-
hydroxybenzonitrile,
N-(4-cyano-2-hyroxyphenyl)-N'-(2-bromophenyl)-N"-(2-hydroxyethyl) guanidine,
N-(4-cyano-2-hyroxyphenyl)-N'-(2-bromophenyl)-N"-(chloromethanesulfonyl)
guanidine,
N-(4-cyano-2-hyroxyphenyl)-N'-(2-bromophenyl)-N"-(2,2-dimethoxyethyl)
guanidine,
4-[[ 1-(2-bromophenyl)-4,5-dihydro-1 H-imidazol-2-yl] amino]-3-
hydroxybenzonitrile,
4-[[4-(2-bromophenyl)-4,5-dihydro-1,1-dioxido-1,2,4-thiadiazol-3-yl] amino]-3-
hydroxybenzonitrile,
4-[[ 1-(2-bromophenyl)-1H-imidazol-2-yl]amino]-3-hydroxybenzonitrile,
4-[(S)-1-(2-Bromo-phenyl)-4-isopropyl-5-oxo-4,5-dihydro-1 H-imidazol-2-
ylamino]-3-hydroxy-benzonitrile ,
3-[(S)-1-(2-Bromo-phenyl)-2-(4-cyano-2-hydroxy-phenylamino)-5-oxo-4,5-dihydro-
1 H-imidazol-4-yl]-propionic acid ethyl ester,
-6-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
[(R)-1-(2-Bromo-phenyl)-2-(4-cyano-2-hydroxy-phenylamino)-5-oxo-4,5-dihydro-1
H-imidazol-4-yl]-acetic acid ethyl ester,
4-[(S)-1-(2,3-Dichloro-phenyl)-4-isopropyl-5-oxo-4,5-dihydro-1-H-imidazol-?-
ylamino]-3-hydroxy-benzonitrile,
4-[(S)-1-(2,3-Dichlorophenyl)-4-isobutyl-5-oxo-4,5-dihydro-1 H-imidazol-2-
ylamino]-3-hydroxy-benzonitrile,
4-[(S)-1-(2,3-Dichlorophenyl)-4-(2-methylsulfanyl-ethyl)-5-oxo-4,5-dihydro-1 H-
imidazol-2-ylamino]-3-hydroxy-benzonitrile,
3-[(S )-2-(4-Cyano-2-hydroxy-phenylamino)-1-(2,3-dichlorophenyl)-5-oxo-4,5-
l0 dihydro-1 H-imidazol-4-yl]-propionic acid ethyl ester,
4-[(S)-1-(2,3-Dichlorophenyl)-4-methyl-5-oxo-4,5-dihydro-1 H-imidazol-2-
ylamino]-3-hydroxy-benzonitrile,
4-[(R)-1-(2,3-Dichlorophenyl)-4-methyl-5-oxo-4,5-dihydro-1 H-imidazol-2-
ylamino]-3-hydroxy-benzonitrile, and
4-[[1-(2-bromophenyl)-4,5-dihydro-5-methoxy-1H-imidazol-2-yl]amino]-3-
hydroxybenzonitrile; or a suitably acceptable salt thereof.
Suitable pharmaceutically acceptable salts are well known to those skilled in
the art and include basic salts of inorganic and organic acids, such as
hydrochloric
acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic
acid,
ethane sulphonic acid, acetic acid, malic acid, tartaric acid, citric acid,
lactic acid,
oxalic acid, succinic acid, fumaric acid, malefic acid, benzoic acid,
salicylic acid,
phenylacetic acid and mandelic acid. In addition, pharmaceutically acceptable
salts
of compounds of Formula (I) may also be formed with a pharmaceutically
acceptable canon, for instance, if a substituent group comprises a carboxy
moiety.
Suitable pharmaceutically acceptable canons are well known to those skilled in
the
art and include alkaline, alkaline earth, ammonium and quaternary ammonium
cations.
The following terms, as used herein, refer to:
~ "halo" - all halogens, that is chloro, fluoro, bromo and iodo.
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
~ "C2_Salkyl" or "alkyl" - both straight and branched chain moieties of 2 to 5
carbon atoms, unless the chain length is otherwise limited, including, but not
limited
to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-
butyl. n-
pentyl and the like.
~ The term "alkenyl" is used herein at all occurrences to mean straight or
branched chain moieties of 2-10 carbon atoms, unless the chain length is
limited
thereto, including, but not limited to ethenyl, 1-propenyl, 2-propenyl, 2-
methyl-1-
propenyl, 1-butenyl, 2-butenyl and the like.
~ "aryl" - phenyl and naphthyl;
~ "heteroaryl" (on its own or in any combination, such as "heteroaryloxy", or
"heteroaryl alkyl") - a 5-10 membered aromatic ring system in which one or
more
rings contain one or more heteroatoms selected from the group consisting of N,
O or
S, such as, but not limited, to pyrrole, pyrazole, furan, thiophene,
quinoline,
isoquinoline, quinazolinyl, pyridine, pyrimidine, oxazole, thiazole,
thiadiazole,
triazole, imidazole, or benzimidazole.
~ "heterocyclic" (on its own or in any combination, such as
"heterocyclicalkyl") - a saturated or partially unsaturated 4-10 membered ring
system in which one or more rings contain one or more heteroatoms selected
from
the group consisting of N, O, or S; such as, but not limited to, pyrrolidine,
piperidine, piperazine, morpholine, tetrahydropyran, or imidazolidine.
The term "arylalkyl" or "heteroarylalkyl" or "heterocyclicalkyl" is used
herein to mean Cl-10 ~kyl, as defined above, attached to an aryl, heteroaryl
or
heterocyclic moiety, as also defined herein, unless otherwise indicated.
Methods of Preparation
The compounds of Formula (I) may be obtained by applying synthetic
procedures, some of which are illustrated in the Schemes below. The synthesis
provided for in these Schemes is applicable for producing compounds of Formula
(I)
having a variety of different R, Rl, and aryl groups which are reacted,
employing
optional substituents which are suitably protected, to achieve compatibility
with the
3o reactions outlined herein. Subsequent deprotection, in those cases, then
affords
-g_
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
compounds of the nature generally disclosed. Once the guanidine nucleus has
been
established, further compounds of these formulas may be prepared by applying
standard techniques for functional group interconversion, well known in the
art.
While the schemes are shown with compounds only of Formula (I) this is merely
for
illustration purposes only.
-9-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
Scheme 1
/ O a Br / O NC / O
\ ~O \ ~O b \ ~O
\N ~N N
H H H
1 2 3
c
NC / OH NC / OH NC O
d /
\ ~ \ ~ N E--- ~ O
NH2 ~ \ N
boc boc
6 5
4
a) Br2, NaOAc, HOAc; b) CuCN, DMF, reflux; c) (BOC)20, DMAP, TEA;
d) K2C03, MeOH; e) TFA
The desired aniline 6-scheme-1 can be prepared from the commercially
available benzoxazolinone 1-scheme-1. Bromide 2-scheme-1 can be prepared from
benzoxazolinone 1-scheme-1 using standard bromination conditions such as
bromine
and sodium acetate in acetic acid. Bromide 2-scheme-1 can be converted to the
1o cyanide 3-scheme-1 using standard procedures such as copper (I) cyanide in
refluxing DMF. The amide 3-scheme-1 can be converted to the BOC protected
compound 4-scheme-1 using standard conditions such as BOC anhydride and
triethylamine with a catalytic amount of dimethylaminopyridine in methylene
chloride or another suitable organic solvent. The oxazolinone 4-scheme-1 can
be
converted to the desired aniline 6-scheme-1 by first hydrolysis to the phenol
5-
scheme-1 using standard conditions such as potassium carbonate in methanol
followed by removal of the BOC protecting group using standard conditions such
as
trifluoroacetic acid in methylene chloride or another suitable organic solvent
to give
the aniline 6-scheme-1.
- 10-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
Scheme 2
NC j OH a NC~~OH S b NC\~ S
ii
\ ~N~NR \ N~NR
NH2 H H
OTBS
1 2
3
or
d
NC / OH b NC / OTBS c NC~~OTBS
i I I~, S
\ NH2 \ NH2 N
1 4 5
a) RNCS; b) TBSCI; c) thiophosgene; d) RNH2
The desired thiourea 3-scheme-2 can be prepared as outlined in scheme 2.
The aniline 1-scheme-2 can be coupled with a commercially available
isothiocyanate
or with an isothiocyanate made from condensing a commercially available amine
with thiophosgene or a thiophosgene equivalent to give the thiourea 2-scheme-
2.
The phenol 2-scheme-2 can be protected as the TBS ether 3-scheme-2 using
1o standard conditions such as TBSCI and imidazole in THF or another suitable
organic
solvent. Alternatively, the amine 1-scheme-2 can be converted to the
isothiocyanate
5-Scheme-2 by first protecting the phenol 1-Scheme-2 with a suitable
protecting
group such as the TBS ether 4-scheme-2 using standard conditions such as TBSCI
and an amine base such as imidazole in THF or another suitable organic
solvent.
The thiourea 5-scheme-2 can be made by condensing the amine 4-scheme 2 with
thiophosgene in the presence of a base such as potassium carbonate. The
desired
thiourea 3-scheme-2 can be prepared from the isothiocyanate 5-scheme-2 by
condensing it with the desired amine in a suitable organic solvent such as
ethanol or
DMF.
-11-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
Scheme 3
NC. / NC
S
a
N ~NR \ N - NR
H
OTBS OTBS
1 2
b, c
NC
a) MsCI, TEA; b) amine, THF ~ N
c) TBAF, THF ~ / O
N
N \
H R
OH
3
The desired lactam 3-scheme-3 can be prepared as outlined in Scheme 3
The carbodiimide 2-Scheme-3 can be prepared from the thiourea 1-scheme-3 using
standard conditions such as an excess amount of methane sulfonyl chloride and
a
suitable amine base such as triethylamine in an organic solvent preferably
methylene
chloride at room temperature. The lactam 3-Scheme-3 can be prepared from the
1o carbodiimide 2-Scheme-3 by first condensing the carbodiimide 2-Scheme-3
with the
desired a-aminoester in a suitable organic solvent such as THF or acetonitrile
followed by removal of the TBS group using standard conditions such as TBAF in
THF at 0°C.
- 12-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
Scheme 4
NC NC / N~OH
a,b
\ N NR
N NR
OTBS OH
1 2
~, c
NC
N ~N
OH R
3
a) 2-aminoethanol, Hunig's base, THF; b) TBAF, THF; c) PPh3, DEAD, THF
The desired dihydroimidazoyl guanidine 3-Scheme-4 can be prepared from
the alcohol 2-Scheme-4 as outlined in Scheme-4. The guanidine 2-Scheme-4 can
be
prepared from the carbodiimide 1-Scheme-4 using standard canditions such as
addition of the primary amine in a suitable organic solvent such as
acetonitrile or
THF followed by removal of the TBS group using standard procedures such as
1o TBAF in THF at 0°C. The cyclic guanidine 3-Scheme-4 can be prepared
from the
guanidine 2-Scheme-4 employing standard Mitsunobu conditons such as
triphenylphosphine and DEAD in a suitable organic solvent such as THF.
-13-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
Scheme 5
Oy
NC NC / N~S~CI
/ ~I a,b
\ \
N - NR ~ N NR
OTBS OH
1 2
Vc
O
NC ~~ ~ O
/ NHS
N N
i
OH R
3
a) chloromethanesulfonamide, Hunig's base, THF; b) TBAF, THF;
c) NaH, DMF
The desired cyclicsulfonamide guanidine 3-Scheme-5 can be prepared from
the chloride 2-Scheme-5 as outlined in Scheme 5. The guanidine 2-Scheme-5 can
be
prepared from the carbodiimide 1-Scheme-5 using the conditions outlined in
schemes 3 and 4. The cyclic guanidine 3-Scheme-5 can be prepared from the
chloride 2-Scheme-5 using standard alkylation conditions such as NaH in a
suitable
organic solvent such as DMF at ambient room temperature or slight heating.
- 14-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
Scheme 6
NC NC ~~OMe
/ a,b ~ i N Y\I
\ OMe
\ ~ N ~NR
N - NR
OTBS OH
y 2
~c
NC~
I N
N ~N
OH R
3
a) 2,2-dimethoxyethylamine, Hunig's base, THF; b) TBAF, THF;
c) pTSA, acetone
The imidazoyl guanidine 3-Scheme-6 can be prepared from the dimethyl
acetal 2-Scheme-6 under standard acid conditions such as pTSA in a suitable
organic
solvent such as acetone. The guanidine 2-Scheme-6 can be prepared form the
carbodiimide 1-Scheme-6 by the methods outline in schemes 3 and 4.
SYNTHETIC EXAMPLES
The invention will now be described by reference to the following examples
which
are merely illustrative and are not to be construed as a limitation of the
scope of the present
invention. All temperatures are given in degrees centigrade, all solvents are
highest
available purity and all reactions run under anhydrous conditions in an argon
atmosphere
unless otherwise indicated.
In the Examples, all temperatures are in degrees Centigrade (°C). Mass
spectra were
performed upon a VG Zab mass spectrometer using fast atom bombardment, unless
otherwise indicated. 1H-NMR (hereinafter "NMR") spectra were recorded at 250
MHz
using a Bruker AM 250 or Am 400 spectrometer. Multiplicities indicated are:
s=singlet,
d=doublet, t=triplet, q=quartet, m=multiplet and br indicates a broad signal.
Sat. indicates a
-15-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
saturated solution, eq indicates the proportion of a molar equivalent of
reagent relative to
the principal reactant.
Example 1
Preparation of 4-((1-(2-bromonhenyl)-4,5-dihydro-5-oxo-1H-imidazol-2-
yllaminol-3-hydroxybenzonitrile.
a) Preparation of 4-bromo-1,2-benzoxazolinone.
To a solution of benzoxazolinone ( 10 g, 74 mmol) in acetic acid (50 mL) at
0°C was added sodium acetate (7.4 g, 74 mmol) and bromine (3.8 mL, 74
mmol)
and the reaction mixture was allowed to warm to rt. After 21 h, the
precipitate was
collected by filtration and washed with water. The filtrate was concentrated
under
reduced pressure to give more solid material which was collected by filtration
followed by washing with water. The material was combined to give 14 g (88%)
of
4-bromo-1,2-benzoxazolinone as a yellow solid which required no further
purification. 1H NMR (400 MHz, DMSO) 8 7.6 (s, 1H), 7.3 (d, 1H), 7.0 (d, 1H);
MS(EI) m/e 212 (M+).
b) Preparation of 4-cyano-1,2-benzoxazolinone.
To a solution of 4-bromo-1,2-benzoxazolinone (5.0 g, 23 mmol) in DMF (11
mL) was added copper (I) cyanide (3.6 g, 39 mmol) and the reaction heated at
165°C. After 6.5 h, the reaction mixture was cooled to rt and water (20
mL) and
sodium cyanide (3.6 g) were added and the reaction heated at 100°C.
After 12 h, the
reaction mixture was extracted with ethyl acetate and the combined organic
layers
were filtered through a scrub pad of silica gel eluting with ethyl acetate.
The filtrate
was concentrated under reduced pressure to give 1.9 g (51%) of 4-cyano-1,2-
benzoxazolinone as a brown solid which required no further purification. 1H
NMR
(400 MHz, DMSO) 8 7.8 (s, 1H), 7.6 (d, 1H), 7.2 (d, 1H).
c) Preparation of N-t-butylacetoxy-4-cyano-1,2-benzoxazolinone.
To a solution of 4-cyano-1,2-benzoxazolinone (1.9 g, 15 mmol) in THF (50
3o mL) at 0°C was added triethylamine (2.5 mL, 18 mmol), DMAP (0.37 g,
3.0 mmol)
- 16-
CA 02374295 2001-11-27
WO 00/72840 PCT/L1S00/14660
and BOC anhydride (4.3 g, 20 mmol) and the reaction mixture was allowed to
warm
to rt. After 1.5 h, the mixture was quenched with water ( 100 mL) and
extracted with
ethyl acetate. The combined organic layers were washed with brine, dried over
anhydrous magnesium sulfate and concentrated under reduced pressure to give
4.3 g
(100%) of N-t-butylacetoxy-4-cyano-1,2-benzoxazolinone as a yellow solid which
required no further purification. 1H NMR (400 MHz, CDC13) 8 7.8 (d, 1H), 7.55
(d,
1H), 7.45 (s, 1H), 1.65 (s, 9H).
d) Preparation of N-t-butylacetoxy-4-cyano-2-hydroxyl aniline.
To a solution of N-t-butylacetoxy-4-cyano-1,2-benzoxazolinone (4.3 g, 16
mmol) in methanol (50 mL) was added potassium carbonate (2.3 g, 16 mmol).
After
1.5 h, the reaction was quenched with water ( 100 mL) and extracted with ethyl
acetate. The combined organic layers were washed with brine, dried over
anhydrous
magnesium sulfate and concentrated under reduced pressure to give 3.1 g (81 %)
of
N-t-butylacetoxy-4-cyano-2-hydroxyl aniline as a brown foam which required no
further purification. 1H NMR (400 MHz, CDCl3) 8 7.7 (d, 1H), 7.15 (s, 1H), 7.1
(d,
1H), 1.5 (s, 9H).
e) Preparation of 4-cyano-2-hydroxyl aniline.
To a solution of N-t-butylacetoxy-4-cyano-2-hydroxyl aniline (3.1 g, 13
mmol) in methylene chloride ( 100 mL) at 0°C was added trifluoroacetic
acid and the
reaction mixture was allowed to warm to rt. After 2.5 h, the reaction was
quenched
with water ( 100 mL) and extracted with ethyl acetate. The combined organic
layers
were washed with brine, dried over anhydrous magnesium sulfate and
concentrated
under reduced pressure. The crude material was purified by flash column
chromatography (50% ethyl acetate/hexanes) to give 1.7 g (96%) of 4-cyano-2-
hydroxyl aniline as a tan solid. 1H NMR (400 MHz, DMSO) 8 7.0 (d, 1H), 6.85
(s,
1H), 6.65 (d, 1H); MS(EI) m/e 134 (M+).
f) Preparation of N-(4-cyano-2-hydroxyphenyl)-N'-(2-bromophenyl) thiourea.
-17-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
To a solution of 4-cyano-2-hydroxyl aniline ( 1.0 g, 7.5 mmol) in ethanol (20
mL) was added 2-bromophenylisothiocyanate ( 1.0 mL, 7.5 mmol). After 24 h, the
reaction mixture was concentrated under reduced pressure to give 2.0 g (77%)
of N-
(4-cyano-2-hydroxyphenyl)-N'-(2-bromophenyl) thiourea as a yellow solid which
required no further purification. 1H NMR (400 MHz, DMSO) 8 10.8 (s, 1H), 10.1
(s,
1H), 9.6 (s, 1H), 8.7 (d, 1H), 7.7 (d, 1H), 7.6 (d, 1H), 7.4 (t, 1H), 7.25 (d,
1H), 7.2 (s,
1H and d, 2H); MS(EI) m/e 229 (100), 348 (75 (M')), 462 (30), 695 (10).
g). Preparation of N-(4-cyano-2-t-butyldimethylsilanoxyphenyl)-N'-(2-
1o bromophenyl) thio urea.
To a solution of N-(4-cyano-2-hydroxyphenyl)-N'-(2-bromophenyl) thio urea
(3.5 g, 10 mmol) in THF (50 mL) at 0°C was added imidazole ( 1.0 g, 15
mmol) and
TBSCI (1.5 g, 10 mmol). After 1 h, the reaction mixture quenched with water
(100
mL) and extracted with ethyl acetate. The combined organic layers were washed
with brine, dried over anhydrous magnesium sulfate and concentrated under
reduced
pressure. The crude material was crystallized from ethyl acetate to give 3.9 g
(84%)
of N-(4-cyano-2-t-butyldimethylsilanoxyphenyl)-N'-(2-bromophenyl) thio urea as
a
yellow solid. 1H NMR (400 MHz, DMSO) 8 9.9 (s, 1H), 9.2 (s, 1H), 8.1 (d, 1H),
7.7
(d, 1 H), 7.6 (d, 1 H), 7.45 (d, 1 H), 7.4 (t, 1 H), 7.35 (s, 1 H), 7.2 (t, 1
H); MS (EI) m/e
347 ( 100 (M+)), 175 (40), 461 (40).
h) Preparation of N-(4-cyano-2-t-butyldimethylsilanoxyphenyl)-N'-(2-
bromophenyl) carbodiimide.
To a solution of N-(4-cyano-2-t-butyldimethylsilanoxyphenyl)-N'-(2-
bromophenyl) thio urea (3.4 g, 7.4 mmol) in methylene chloride (40 mL) at
0°C was
added triethylamine (3.1 mL, 22 mmol), DMAP (20 mg) and methane sulfonyl
chloride ( 1.1 mL, 15 mmol). After 25 min, the reaction mixture was quenched
with
water ( 100 mL) and extracted with ethyl acetate. The combined organic layers
were
washed with brine, dried over anhydrous magnesium sulfate and concentrated
under
reduced pressure to give 3.3 g ( 100%) of N-(4-cyano-2-t-
-18-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
butyldimethylsilanoxyphenyl)-N'-(2-bromophenyl) carbodiimide as a yellow solid
which required no further purification. 1H NMR (400 MHz, DMSO) 8 7.7 (d, 1H),
7.45 (d, 1H), 7.4 (m, 4H), 7.15 (t, 1H).
i) Standard procedure for the synthesis of diphenylguanidines. Preparation of
4-[[1-
(2-bromophenyl)-4,5-dihydro-5-oxo-1 H-imidazol-2-yl]amino]-3-
hydroxybenzonitrile.
To a solution of N-(4-cyano-2-t-butyldimethylsilanoxyphenyl)-N'-(2-
bromophenyl) carbodiimide ( 112 mg, 0.26 mmol) in acetonitrile (2 mL) was
added
l0 diisopropylethylamine (0.10 mL, 0.57 mmol) and glycine ethyl ester
hydrochloride
(40 mg, 0.29 mmol). After 30 min, the mixture was concentrated under reduced
temperature. The crude residue was diluted with THF ( 1 mL) and methanol (0.1
mL) and TBAF (0.29 mL, 0.29 mmol) was added at 0°C. After 5 min, the
reaction
mixture was quenched with water (2 mL) and extraced with ethyl acetate. The
combined organic layers were washed with brine, dried over anhydrous magnesium
sulfate and concentrated under reduced pressure. The crude material was
purified by
recrystallization from methylene chloride and hexanes to give 70 mg (73%) of 4-
[[1-
(2-bromophenyl)-4,5-dihydro-5-oxo-1 H-imidazol-2-yl]amino]-3-
hydroxybenzonitrile as a tan powder. 1 H NMR (400 MHz, MeOD) 8 7.6 ( 1 H, d),
7.55 (1H, d), 7.4 (1H, s), 7.3 (2H, dd), 7.0 (2H, m); MS(EI) m/e 372 (100
(M+)).
k) Preparation of N-(4-cyano-2-hyroxyphenyl)-N'-(2-bromophenyl)-N"-(2-
hydroxyethyl) guanidine.
The standard procedure was followed using N-(4-cyano-2-t-
butyldimethylsilanoxyphenyl)-N'-(2-bromophenyl) carbodiimide (105 mg, 0.24
mmol), diisopropylethylamine (45 ~L, 0.26 mmol), ethanolamine ( 16 ~L, 0.26
mmol) and TBAF (0.53 mL, 0..53 mmol) in THF (2 mL) and methanol (0.1 mL) to
give 52 mg (57%) of N-(4-cyano-2-hyroxyphenyl)-N'-(2-bromophenyl)-N"-(2-
hydroxyethyl) guanidine as a tan powder. 1H NMR (400 MHz, DMSO) 8 7.55 (2H,
-19-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
m), 7.2 (1H, t), 7.1 (1H, d), 7.05 (1H, s), 6.95 (1H, d), 6.85 (1H, t); MS(EI)
m/e 376
( 100 (M+)), 490 (20).
1) Preparation of N-(4-cyano-2-hyroxyphenyl)-N'-(2-bromophenyl)-N"-
(chloromethanesulfonyl) guanidine.
The standard procedure was followed using N-(4-cyano-2-t-
butyldimethylsilanoxyphenyl)-N'-(2-bromophenyl) carbodiimide (220 mg, 0.51
mmol), diisopropylethylamine (63 ~L, 0.56 mmol), chloromethylsulfonamide (72
mg, 0.56 mmol) and TBAF (0.13 mL, 0.13 mmol) in THF (1 mL) and methanol (0.1
to mL) to give 16 mg (32%) of N-(4-cyano-2-hyroxyphenyl)-N'-(2-bromophenyl)-N"-
(chloromethanesulfonyl) guanidine as a tan powder. 1H NMR (400 MHz, MeOD) 8
7.85 ( 1 H, d), 7.7 ( 1 H, d), 7.5 ( 1 H, d), 7.4 ( 1 H, t), 7.25 ( 1 H, t),
7.15 ( 1 H, d), 7.05
(1H, s), 4.7 (2H, s); MS(EI) m/e 887 (100 (Mx2)), 490 (20).
m) Preparation of N-(4-cyano-2-hyroxyphenyl)-N'-(2-bromophenyl)-N"-(2,2-
dimethoxyethyl) guanidine.
The standard procedure was followed using N-(4-cyano-2-t-
butyldimethylsilanoxyphenyl)-N'-(2-bromophenyl) carbodiimide (250 mg, 0.58
mmol), diisopropylethylamine (72 ~L, 0.64 mmol), 2,2-dimethoxyethylamine (70
~,
0.64 mmol) and TBAF (0.70 mL, 0.70 mmol) in THF (6 mL) and methanol (0.1 mL)
to give 170 mg (70%) of N-(4-cyano-2-hyroxyphenyl)-N'-(2-bromophenyl)-N"-(2,2-
dimethoxyethyl) guanidine as a tan powder. 1 H NMR (400 MHz, MeOD) 8 7.6 ( 1
H,
m), 7.5 (1H, d), 7.15 (1H, t), 7.1 (1H, d), 7.0 (1H, s), 6.9 (1H, d), 6.8 (1H,
t), 4.45
(1H, t), 3.3 (6H, s); MS(EI) m/e 420 (100 (M+)).
n) Preparation of 4-[[1-(2-bromophenyl)-4,5-dihydro-1H-imidazol-2-yl]amino]-3-
hydroxybenzonitrile.
To a solution of N-(4-cyano-2-hyroxyphenyl)-N'-(2-bromophenyl)-N"-(2-
hydroxyethyl) guanidine (46.2 mg, .12 mmol) in THF (2 mL) was added
triphenylphosphine (140 mg, 0.53 mmol) and DEAD (41 ~,L, .26 mmol) at rt.
After
-20-
CA 02374295 2001-11-27
WO 00/72840 PCT/LTS00/14660
2.5 h, the reaction was quenched with water ( 1 mL) and extracted with ethyl
acetate.
The combined organic layers were washed with brine, dried over anhydrous
magnesium sulfate and concentrated under reduced pressure. The crude residue
wash purified by column chromatography ( 10% MeOH in ethyl acetate) to give 28
mg (65%) of 4-[[1-(2-bromophenyl)-4,5-dihydro-1H-imidazol-2-yl]amino]-3-
hydroxybenzonitrile as a tan powder. 1H NMR (400 MHz, CDCl3) 8 7.6 (1H, d),
7.4
(2H, m), 7.2 (1H, t), 7.0 (3H, d and s), 3.95 (2H, t), 3.75 (2H, t); MS(EI)
m/e 358
( 100 (M+)).
0) Preparation of 4-[[4-(2-bromophenyl)-4,5-dihydro-1,1-dioxido-1,2,4-
thiadiazol-
3-yl]amino]-3-hydroxybenzonitrile.
To a solution of N-(4-cyano-2-hyroxyphenyl)-N'-(2-bromophenyl)-N"-
(chloromethanesulfonyl) guanidine (220 mg, 0.39 mmol) in DMF (4 mL) was added
sodium hydride (20 mg, 0.78 mmol) at rt. After 24 h, the reaction was quenched
with
water (5 mL) and extracted with ethyl acetate. The combined organic layers
were washed
with brine, dried over anhydrous magnesium sulfate and concentrated under
educed
pressure. The crude residue wash purified by column chromatography (75% ethyl
acetate
in hexanes) to give 100 mg (63%) of 4-[[4-(2-bromophenyl)-4,5-dihydro-1,1-
dioxido-
1,2,4-thiadiazol-3-yl]amino]-3-hydroxybenzonitrile as a tan powder. 1H NMR
(400 MHz,
2o CDCl3) b 8.1 ( 1 H, d), 7.85 ( 1 H, d), 7.7 ( 1 H, d), 7.6 ( 1 H, t), 7.5 (
1 H, t), 7.2 ( 1 H, d), 7.0
(1H, s), 4.75 (2H, q); MS(EI) m/e 406 (100 (M-)).
-21-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
p) Preparation of 4-[[1-(2-bromophenyl)-1H-imidazol-2-yl]amino]-3-
hydroxybenzonitrile.
To a solution of N-(4-cyano-2-hyroxyphenyl)-N'-(2-bromophenyl)-N"-(2,2-
dimethoxyethyl) guanidine ( 120 mg, 0.28 mmol) in acetone ( 1 mL) was added
pTSA
( 1 mg) at rt. After 24 h, the reaction was quenched with water (5 mL) and
extracted
with ethyl acetate. The combined organic layers were washed with brine, dried
over
anhydrous magnesium sulfate and concentrated under reduced pressure. The crude
residue wash purified by column chromatography ( 100% ethyl acetate) to give
12
mg (12%) of 4-[(1-(2-bromophenyl)-1H-imidazol-2-yl]amino]-3-
hydroxybenzonitrile as a tan powder and 4 mg (4%) of 4-[[1-(2-bromophenyl)-4,5-
dihydro-5-methoxy-1H-imidazol-2-yl]amino]-3-hydroxybenzonitrile as a tan
powder.
4-[[1-(2-bromophenyl)-1H-imidazol-2-yl]amino]-3-hydroxybenzonitrile: 1H NMR
(400 MHz, MeOD) 8 7.45 (2H, t), 7.35 ( 1 H, d), 7.3 ( 1 H, s), 7.25 ( 1 H, d),
7.15 ( 1 H,
t), 7.1 (1H, s), 7.0 (1H, s), 6.75 (1H, t); MS(EI) m/e 356 (100 (M+)).
4-[ [ 1-(2-bromophenyl)-4,5-dihydro-5-methoxy-1 H-imidazol-2-yl]amino]-3-
hydroxybenzonitrile: 1 H NMR (400 MHz, MeOD) b 7.65 ( 1 H, t), 7.55 ( 1 H, d),
7.25
( 1 H, t), 7.2 (2H, s and d), 7.05 ( 1 H, d), 6.95 ( 1 H, t), 5.8 ( 1 H, d),
3.8 ( 1 H, dd), 3.5
(1H, dd), 3.25 (3H, s); MS(EI) m/e 388 (100 (M+)).
2o METHOD OF TREATMENT
The compounds of Formula (I) or a pharmaceutically acceptable salt thereof
can be used in the manufacture of a medicament for the prophylactic or
therapeutic
treatment of any disease state in a human, or other mammal, which is
exacerbated or
caused by excessive or unregulated IL-8 cytokine production by such mammal's
cell,
such as but not limited to monocytes and/or macrophages, or other chemokines
which bind to the IL-8 a or (3 receptor, also referred to as the type I or
type II
receptor.
Accordingly, the present invention provides a method of treating a
chemokine mediated disease, wherein the chemokine is one which binds to an IL-
8
oc or (3 receptor and which method comprises administering an effective amount
of a
-22-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
compound of Formula (I) or a pharmaceutically acceptable salt thereof. In
particular, the chemokines are IL-8, GROoc, GROG, GRO~y, NAP-2 or ENA-78.
For purposes herein, the compounds of Formula (I) and (II) all have the same
dosages, and formulations as that of Formula (I) are used interchangeably.
The compounds of Formula (I) are administered in an amount sufficient to
inhibit cytokine function, in particular IL-8, GROoc, GROG, GROy, NAP-2 or ENA-
78,
such that they are biologically regulated down to normal levels of
physiological
function, or in some case to subnormal levels, so as to ameliorate the disease
state.
Abnormal levels of IL-8, GROG, GR0~3, GROy, NAP-2 or ENA-78 for instance in
the
context of the present invention, constitute: (i) levels of free IL-8 greater
than or equal
to 1 picogram per mL; (ii) any cell associated IL-8, GROoc, GR0~3, GRO~y, NAP-
2 or
ENA-78 above normal physiological levels; or (iii) the presence IL-8, GROG,
GROG,
GROy, NAP-2 or ENA-78 above basal levels in cells or tissues in IL-8, GROG,
GROG,
GROy, NAP-2 or ENA-78 respectively, is produced.
There are many disease states in which excessive or unregulated IL-8
production is implicated in exacerbating and/or causing the disease. Chemokine
mediated diseases include psoriasis, atopic dermatitis, arthritis, asthma,
chronic
obstructive pulmonary disease, adult respiratory distress syndrome,
inflammatory
bowel disease, Crohn's disease, ulcerative colitis, stroke, septic shock,
endotoxic
shock, gram negative sepsis, toxic shock syndrome, cardiac and renal
reperfusion
injury, glomerulonephritis, thrombosis, graft vs. host reaction, alzheimers
disease,
allograft rejections, malaria, restinosis, angiogenesis, atherosclerosis,
osteoporosis,
gingivitis or undesired hematopoietic stem cells release.
These diseases are primarily characterized by massive neutrophil infiltration,
T-cell infiltration, or neovascular growth, and are associated with increased
IL-8,
GROa, GROG, GROy or NAP-2 production which is responsible for the chemotaxis
of neutrophils into the inflammatory site or the directional growth of
endothelial
cells. In contrast to other inflammatory cytokines (IL-l, TNF, and IL-6), IL-
8,
GROa., GR0~3, GROy or NAP-2 has the unique property of promoting neutrophil
chemotaxis, enzyme release including but not limited to elastase release as
well as
-23-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
superoxide production and activation. The a-chemokines but particularly, GROG,
GROG, GRO~y or NAP-2, working through the IL-8 type I or II receptor can
promote
the neovascularization of tumors by promoting the directional growth of
endothelial
cells. Therefore, the inhibition of IL-8 induced chemotaxis or activation
would lead
to a direct reduction in the neutrophil infiltration.
Recent evidence also implicates the role of chemokines in the treatment of
HIV infections, Littleman et al., Nature 381, pp 661 ( 1996) and Koup et al.,
Nature
381, pp 667 (1996).
The present invention also provides for a means of treating, in an acute
setting, as
to well as preventing, in those individuals deemed susceptible to, CNS
injuries by the
chemokine receptor antagonist compounds of Formula (I).
CNS injuries as defined herein include both open or penetrating head trauma,
such as by surgery, or a closed head trauma injury, such as by an injury to
the head
region. Also included within this definition is ischemic stroke, particularly
to the
brain area.
Ischemic stroke may be defined as a focal neurologic disorder that results
from insufficient blood supply to a particular brain area, usually as a
consequence of
an embolus, thrombi, or local atheromatous closure of the blood vessel. The
role of
inflammatory cytokines in this area has been emerging and the present
invention
2o provides a mean for the potential treatment of these injuries. Relatively
little
treatment, for an acute injury such as these has been available.
TNF-a is a cytokine with proinflammatory actions, including endothelial
leukocyte adhesion molecule expression. Leukocytes infiltrate into ischemic
brain
lesions and hence compounds which inhibit or decrease levels of TNF would be
useful for treatment of ischemic brain injury. See Liu et al., Stroke, Vol.
25., No. 7,
pp 1481-88 (1994) whose disclosure is incorporated herein by reference.
Models of closed head injuries and treatment with mixed 5-LOCO agents is
discussed in Shohami et al., J. of Vaisc & Clinical Physiology and
Pharmacology,
Vol. 3, No. 2, pp. 99-107 (1992) whose disclosure is incorporated herein by
-24-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
reference. Treatment which reduced edema formation was found to improve
functional outcome in those animals treated.
The compounds of Formula (I) are administered in an amount sufficient to
inhibit binding to the IL-8 alpha or beta receptors such as evidenced by a
reduction
in neutrophil chemotaxis and activation. The discovery that the compounds of
Formula (I) are inhibitors of IL-8 binding is based upon the effects of the
compounds of Formulas (I) in the in vitro receptor binding assays which are
described herein. The compounds of Formula (I) have been shown, in some
instances, to be dual inhibitors of both recombinant type I and type II IL-8
receptors.
Preferably the compounds are inhibitors of only one receptor, more preferably
Type
II.
As used herein, the term "IL-8 mediated disease or disease state" refers to
any and all disease states in which IL-8, GROa, GR0~3, GRO~y, NAP-2 or ENA-78
plays a role, either by production of IL-8, GROa, GROG, GROy, NAP-2 or ENA-78
themselves, or by IL-8, GROG, GROG, GROy, NAP-2 or ENA-78 causing another
monokine to be released, such as but not limited to IL-1, IL-6 or TNF. A
disease
state in which, for instance, IL-1 is a major component, and whose production
or
action, is exacerbated or secreted in response to IL-8, would therefore be
considered
a disease stated mediated by IL-8.
2o As used herein, the term "chemokine mediated disease or disease state"
refers
to any and all disease states in which a chemokine which binds to an IL-8 a or
(3
receptor plays a role, such as but not limited IL-8, GROa, GROG, GROy, NAP-2
or
ENA-78. This would include a disease state in which, IL-8 plays a role, either
by
production of IL-8 itself, or by IL-8 causing another monokine to be released,
such
as but not limited to IL-1, IL-6 or TNF. A disease state in which, for
instance, IL-1
is a major component, and whose production or action, is exacerbated or
secreted in
response to IL-8, would therefore be considered a disease stated mediated by
IL-8.
As used herein, the term "cytokine" refers to any secreted polypeptide that
affects the functions of cells and is a molecule which modulates interactions
between
3o cells in the immune, inflammatory or hematopoietic response. A cytokine
includes,
- 25 -
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
but is not limited to, monokines and lymphokines, regardless of which cells
produce
them. For instance, a monokine is generally referred to as being produced and
secreted by a mononuclear cell, such as a macrophage and/or monocyte. Many
other
cells however also produce monokines, such as natural killer cells,
fibroblasts,
basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow
stromal cells,
epideral keratinocytes and B-lymphocytes. Lymphokines are generally referred
to as
being produced by lymphocyte cells. Examples of cytokines include, but are not
limited to, Interleukin-1 (IL-1), Interleukin-6 (IL,-6), Interleukin-8 (IL-8),
Tumor
Necrosis Factor-alpha (TNF-a) and Tumor Necrosis Factor beta (TNF-13).
As used herein, the term "chemokine" refers to any secreted polypeptide that
affects the functions of cells and is a molecule which modulates interactions
between
cells in the immune, inflammatory or hematopoietic response, similar to the
term
"cytokine" above. A chemokine is primarily secreted through cell
transmembranes
and causes chemotaxis and activation of specific white blood cells and
leukocytes,
neutrophils, monocytes, macrophages, T-cells, B-cells, endothelial cells and
smooth
muscle cells. Examples of chemokines include, but are not limited to, IL-8,
GRO-a,
GRO-(3, GRO-y, NAP-2, ENA-78, IP-10, MIP-la, MIP-(3, PF4, and MCP 1, 2, and
3.
In order to use a compound of Formula (I) or a pharmaceutically acceptable
salt thereof in therapy, it will normally be formulated into a pharmaceutical
composition in accordance with standard pharmaceutical practice. This
invention,
therefore, also relates to a pharmaceutical composition comprising an
effective, non-
toxic amount of a compound of Formula (I) and a pharmaceutically acceptable
carrier or diluent.
Compounds of Formula (I), pharmaceutically acceptable salts thereof and
pharmaceutical compositions incorporating such may conveniently be
administered
by any of the routes conventionally used for drug administration, for
instance, orally,
topically, parenterally or by inhalation. The compounds of Formula (I) may be
administered in conventional dosage forms prepared by combining a compound of
Formula (I) with standard pharmaceutical carriers according to conventional
-26-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
procedures. The compounds of Formula (I) may also be administered in
conventional dosages in combination with a known, second therapeutically
active
compound. These procedures may involve mixing, granulating and compressing or
dissolving the ingredients as appropriate to the desired preparation. It will
be
appreciated that the form and character of the pharmaceutically acceptable
character
or diluent is dictated by the amount of active ingredient with which it is to
be
combined, the route of administration and other well-known variables. The
carriers) must be "acceptable" in the sense of being compatible with the other
ingredients of the formulation and not deleterious to the recipient thereof.
The pharmaceutical carrier employed may be, for example, either a solid or
liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc,
gelatin, agar,
pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of
liquid
carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the
carrier or
diluent may include time delay material well known to the art, such as
glyceryl
mono-stearate or glyceryl distearate alone or with a wax.
A wide variety of pharmaceutical forms can be employed. Thus, if a solid
carrier is used, the preparation can be tableted, placed in a hard gelatin
capsule in
powder or pellet form or in the form of a troche or lozenge. The amount of
solid
carrier will vary widely but preferably will be from about 25mg. to about 1g.
When
a liquid carrier is used, the preparation will be in the form of a syrup,
emulsion, soft
gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous
liquid
suspension.
Compounds of Formula (I) may be administered topically, that is by non-
systemic administration. This includes the application of a compound of
Formula (I)
externally to the epidermis or the buccal cavity and the instillation of such
a
compound into the ear, eye and nose, such that the compound does not
significantly
enter the blood stream. In contrast, systemic administration refers to oral,
intravenous, intraperitoneal and intramuscular administration.
Formulations suitable for topical administration include liquid or semi-liquid
3o preparations suitable for penetration through the skin to the site of
inflammation
-27-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
such as liniments, lotions, creams, ointments or pastes, and drops suitable
for
administration to the eye, ear or nose. The active ingredient may comprise,
for
topical administration, from 0.001 % to 10% w/w, for instance from 1 % to 2%
by
weight of the Formulation. It may however comprise as much as 10% w/w but
preferably will comprise less than 5 % w/w, more preferably from 0.1 % to 1 %
w/w
of the Formulation.
Lotions according to the present invention include those suitable for
application to the skin or eye. An eye lotion may comprise a sterile aqueous
solution
optionally containing a bactericide and may be prepared by methods similar to
those
to for the preparation of drops. Lotions or liniments for application to the
skin may
also include an agent to hasten drying and to cool the skin, such as an
alcohol or
acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or
arachis
oil.
Creams, ointments or pastes according to the present invention are semi-solid
formulations of the active ingredient for external application. They may be
made by
mixing the active ingredient in finely-divided or powdered form, alone or in
solution
or suspension in an aqueous or non-aqueous fluid, with the aid of suitable
machinery, with a greasy or non-greasy base. The base may comprise
hydrocarbons
such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a
mucilage;
2o an oil of natural origin such as almond, corn, arachis, castor or olive
oil; wool fat or
its derivatives or a fatty acid such as steric or oleic acid together with an
alcohol
such as propylene glycol or a macrogel. The formulation may incorporate any
suitable surface active agent such as an anionic, cationic or non-ionic
surfactant such
as a sorbitan ester or a polyoxyethylene derivative thereof. Suspending agents
such
as natural gums, cellulose derivatives or inorganic materials such as
silicaceous
silicas, and other ingredients such as lanolin, may also be included.
Drops according to the present invention may comprise sterile aqueous or
oily solutions or suspensions and may be prepared by dissolving the active
ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal
agent
3o and/or any other suitable preservative, and preferably including a surface
active
-28-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
agent. The resulting solution may then be clarified by filtration, transferred
to a
suitable container which is then sealed and sterilized by autoclaving or
maintaining
at 98-100 °C. for half an hour. Alternatively, the solution may be
sterilized by
filtration and transferred to the container by an aseptic technique. Examples
of
bactericidal and fungicidal agents suitable for inclusion in the drops are
phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01 %) and
chlorhexidine acetate (0.01 %). Suitable solvents for the preparation of an
oily
solution include glycerol, diluted alcohol and propylene glycol.
Compounds of formula (I) may be administered parenterally, that is by
intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal
or
intraperitoneal administration. The subcutaneous and intramuscular forms of
parenteral administration are generally preferred. Appropriate dosage forms
for such
administration may be prepared by conventional techniques. Compounds of
Formula (I) may also be administered by inhalation, that is by intranasal and
oral
inhalation administration. Appropriate dosage forms for such administration,
such
as an aerosol formulation or a metered dose inhaler, may be prepared by
conventional techniques.
For all methods of use disclosed herein for the compounds of Formula (I),
the daily oral dosage regimen will preferably be from about 0.01 to about 80
mg/kg
of total body weight. The daily parenteral dosage regimen about 0.001 to about
80
mg/kg of total body weight. The daily topical dosage regimen will preferably
be
from 0.1 mg to 150 mg, administered one to four, preferably two or three times
daily. The daily inhalation dosage regimen will preferably be from about 0.01
mg/kg to about 1 mg/kg per day. It will also be recognized by one of skill in
the art
that the optimal quantity and spacing of individual dosages of a compound of
Formula (I) or a pharmaceutically acceptable salt thereof will be determined
by the
nature and extent of the condition being treated, the form, route and site of
administration, and the particular patient being treated, and that such
optimums can
be determined by conventional techniques. It will also be appreciated by one
of skill
3o in the art that the optimal course of treatment, i.e., the number of doses
of a
-29-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
compound of Formula (I) or a pharmaceutically acceptable salt thereof given
per day
for a defined number of days, can be ascertained by those skilled in the art
using
conventional course of treatment determination tests.
The invention will now be described by reference to the following biological
examples which are merely illustrative and are not to be construed as a
limitation of
the scope of the present invention.
BIOLOGICAL EXAMPLES
The IL-8, and Gro-a chemokine inhibitiory effects of compounds of the
present invention were determined by the following in vitro assay:
to Receutor Binding Assays:
~125I~ ~_g (human recombinant) was obtained from Amersham Corp.,
Arlington Heights, IL, with specific activity 2000 Ci/mmol. Gro-a was obtained
from NEN- New England Nuclear. All other chemicals were of analytical grade.
High levels of recombinant human IL-8 type a and (3 receptors were
individually
expressed in Chinese hamster ovary cells as described previously (Holmes, et
al.,
Science, 1991, 253, 1278). The Chinese hamster ovary membranes were .
homogenized according to a previously described protocol (Haour, et al., J
Biol
Chem., 249 pp 2195-2205 ( 1974)). Except that the homogenization buffer was
changed to IOmM Tris-HCL, 1mM MgS04, 0.5mM EDTA (ethylene-diaminetetra-
2o acetic acid), ImMPMSF (oc-toluenesulphonyl fluoride), 0.5 mg/L Leupeptin,
pH 7.5.
Membrane protein concentration was determined using Pierce Co. micro-assay kit
using bovine serum albumin as a standard. All assays were performed in a 96-
well
micro plate format. Each reaction mixture contained 1251 IL-8 (0.25 nM) or
1251
Gro-a and 0.5 pg/mL of IL-8Ra or 1.0 ~g/mL of IL-8R(3 membranes in 20 mM Bis-
Trispropane and 0.4 mM Tris HCl buffers, pH 8.0, containing 1.2 mM MgS04, 0.1
mM EDTA, 25 mM NaCI and 0.03% CHAPS. In addition, drug or compound of
interest was added which had been pre-dissolved in DMSO so as to reach a final
concentration of between O.OlnM and 100 uM. The assay was initiated by
addition
of 1251-R,_g. After 1 hour at room temperature the plate was harvested using a
Tomtec 96-well harvester onto a glass fiber filtermat blocked with 1 %
-30-
CA 02374295 2001-11-27
WO 00/72840 PCT/LTS00/14660
polyethylenimine/0.5% BSA and washed 3 times with 25 mM NaCI, 10 mM
TrisHCl, 1 mM MgS04, 0.5 mM EDTA, 0.03 % CHAPS, pH 7.4. The filter was
then dried and counted on the Betaplate liquid scintillation counter. The
recombinant IL-8 Ra, or Type I, receptor is also referred to herein as the non-
permissive receptor and the recombinant IL-8 R~3, or Type II, receptor is
referred to
as the permissive receptor.
All of the exemplified compounds of Formulas (I) noted herein in the
Synthetic Chemistry Section, Example 1 to 15, demonstrated an IC50 from about
45
to about <1 pg/mL in the permissive models for IL-8 receptor inhibition. Of
those
to compounds tested, Examples 1 to 12 were also found to be inhibitors of Gro-
a,
binding at about the same level.
Chemotaxis Assay
The in vitro inhibitory properties of these compounds are determined in the
neutrophil chemotaxis assay as described in Current Protocols in Immunology,
vol I,
Suppl 1, Unit 6.12.3., whose disclosure is incorporated herein by reference in
its
entirety. Neutrophils where isolated from human blood as described in Current
Protocols in Immunology Vol I, Suppl 1 Unit 7.23.1, whose disclosure is
incorporated herein by reference in its entirety. The chemoattractants IL-8,
GRO-oc,
GRO-(3, GRO-y and NAP-2 are placed in the bottom chamber of a 48 multiwell
2o chamber (Neuro Probe, Cabin John, MD) at a concentration between 0.1 and
100
nM. The two chambers are separated by a Sum polycarbonate filter. When
compounds of this invention are tested, they are mixed with the cells (0.001 -
1000
nM) just prior to the addition of the cells to the upper chamber. Incubation
is
allowed to proceed for between about 45 and 90 min at about 37oC in a
humidified
incubator with 5% C02. At the end of the incubation period, the polycarbonate
membrane is removed and the top side washed, the membrane then stained using
the
Diff Quick staining protocol (Baxter Products, McGaw Park,1L, USA). Cells
which
have chemotaxed to the chemokine are visually counted using a microscope.
Generally, four fields are counted for each sample, these numbers are averaged
to
3o give the average number of cells which had migrated. Each sample is tested
in
-31 -
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
triplicate and each compound repeated at least four times. To certain cells
(positive
control cells) no compound is added, these cells represent the maximum
chemotactic
response of the cells. In the case where a negative control (unstimulated) is
desired,
no chemokine is added to the bottom chamber. The difference between the
positive
control and the negative control represents the chemotactic activity of the
cells.
Elastase Release Assay:
The compounds of this invention are tested for their ability to prevent
Elastase release from human neutrophils. Neutrophils are isolated from human
blood as described in Current Protocols in Immunology Vol I, Suppl 1 Unit
7.23.1.
to PMNs 0.88 x 106 cells suspended in Ringer's Solution (NaCI 118, KCl 4.56,
NaHC03 25, KH2P04 1.03, Glucose 11.1, HEPES 5 mM, pH 7.4) are placed in
each well of a 96 well plate in a volume of 50 u1. To this plate is added the
test
compound (0.001 - 1000 nM) in a volume of 50 u1, Cytochalasin B in a volume of
50 u1 (20ug/ml) and Ringers buffer in a volume of 50 u1. These cells are
allowed to
warm (37 °C, 5°1o C02, 95% RH) for 5 min before IL-8, GROG,
GROG, GROy or
NAP-2 at a final concentration of 0.01 - 1000 nM was added. The reaction is
allowed to proceed for 45 min before the 96 well plate is centrifuged (800 xg
5 min)
and 100 u1 of the supernatant removed. This suppernatant is added to a second
96
well plate followed by an artificial elastase substrate (MeOSuc-Ala-Ala-Pro-
Val-
2o AMC, Nova Biochem, La Jolla, CA) to a final concentration of 6 ug/ml
dissolved in
phosphate buffered saline. Immediately, the plate is placed in a fluorescent
96 well
plate reader (Cytofluor 2350, Millipore, Bedford, MA) and data collected at 3
min
intervals according to the method of Nakajima et al J. Biol Chem 254 4027
(1979).
The amount of Elastase released from the PMNs is calculated by measuring the
rate
of MeOSuc-Ala-Ala-Pro-Val-AMC degradation.
TNF-a in Traumatic Brain In_iury Assay
The present assay provides for examination of the expression of tumor
necrosis factor mRNA in specfic brain regions which follow experimentally
induced
lateral fluid-percussion traumatic brain injury (TBI) in rats. Adult Sprague-
Dawley
rats (n=42) were anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and
-32-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
subjected to lateral fluid-percussion brain injury of moderate severity (2.4
atm.)
centered over the left temporaparietal cortex (n=18), or "sham" treatment
(anesthesia
and surgery without injury, n=18). Animals are sacrificed by decapitation at
1, 6 and
24 hr. post injury, brains removed, and tissue samples of left (injured)
parietal cortex
(LC), corresponding area in the contralateral right cortex (RC), cortex
adjacent to
injured parietal cortex (LA), corresponding adjacent area in the right cortex
(RA),
left hippocampus (LH) and right hippocampus (RH) are prepared. Total RNA was
isolated and Northern blot hybridization is performed and quantitated relative
to an
TNF-a positive control RNA (macrophage = 100%). A marked increase of TNF- a
to mRNA expression is observed in LH (104~17% of positive control, p < 0.05
compared with sham), LC ( 105~21 %, p< 0.05) and LA (69~8%, p < 0.01 ) in the
traumatized hemisphere 1 hr. following injury. An increased TNF- a mRNA
expression is also observed in LH (46~8%, p < 0.05), LC (30~3%, p < 0.01) and
LA
(32~3%, p < 0.01) at 6 hr. which resolves by 24 hr. following injury. In the
contralateral hemisphere, expression of TNF- a mRNA is increased in RH (46~2%,
p < 0.01), RC (4~3%) and RA (22~8%) at 1 hr. and in RH (28~11%), RC (7~5%)
and RA (26~6%, p < 0.05) at 6 hr. but not at 24 hr. following injury. In sham
(surgery without injury) or naive animals, no consistent changes in expression
of
TNF- a mRNA are observed in any of the 6 brain areas in either hemisphere at
any
times. These results indicate that following parasagittal fluid-percussion
brain
injury, the temporal expression of TNF-a mRNA is altered in specific brain
regions,
including those of the non-traumatized hemisphere. Since TNF-a is able to
induce
nerve growth factor (NGF) and stimulate the release of other cytokines from
activated astrocytes, this post-traumatic alteration in gene expression of TNF-
a plays
an important role in both the acute and regenerative response to CNS trauma.
CNS Iniury model for IL-(3 mRNA
This assay characterizes the regional expression of interleukin-113 (IL-113)
mRNA in specific brain regions following experimental lateral fluid-percussion
traumatic brain injury (TBI) in rats. Adult Sprague-Dawley rats (n=42) are
3o anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and subjected to
lateral
-33-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
fluid-percussion brain injury of moderate severity (2.4 atm.) centered over
the left
temporaparietal cortex (n=18), or "sham" treatment (anesthesia and surgery
without injury). Animals are sacrificed at l, 6 and 24 hr. post injury, brains
removed, and tissue samples of left (injured) parietal cortex (LC),
corresponding
area in the contralateral right cortex (RC), cortex adjacent to injured
parietal
cortex (LA), corresponding adjacent area in the right cortex (RA), left
hippocampus (LH) and right hippocampus (RH) are prepared. Total RNA is
isolated and Northern blot hybridization was performed and the quantity of
brain
tissue IL-113 mRNA is presented as percent relative radioactivity of IL-113
positive
1o macrophage RNA which was loaded on same gel. At 1 hr. following brain
injury,
a marked and significant increase in expression of IL-113 mRNA is observed in
LC
(20.0~0.7% of positive control, n=6, p < 0.05 compared with sham animal), LH
(24.5~0.9%, p < 0.05) and LA (21.5~3.1 %, p < 0.05) in the injured hemisphere,
which remained elevated up to 6 hr. post injury in the LC (4.0~0.4%, n=6,
p < 0.05) and LH (5.0~1.3%, p < 0.05). In sham or naive animals, no expression
of IL-113 mRNA is observed in any of the respective brain areas. These results
indicate that following TBI, the temporal expression of IL-113 mRNA is
regionally
stimulated in specific brain regions. These regional changes in cytokines,
such as
IL-113 play a role in the post-traumatic.
2o All publications, including but not limited to patents and patent
applications, cited in this specification are herein incorporated by reference
as if
each individual publication were specifically and individually indicated to be
incorporated by reference herein as though fully set forth.
The above description fully discloses the invention including preferred
embodiments thereof. Modifications and improvements of the embodiments
specifically disclosed herein are within the scope of the following claims.
Without further elaboration, it is believed that one skilled in the area can,
using
the preceding description, utilize the present invention to its fullest
extent.
Therefore the Examples herein are to be construed as merely illustrative and
not a
limitation of the scope of the present invention in any way. The embodiments
of
-34-
CA 02374295 2001-11-27
WO 00/72840 PCT/US00/14660
the invention in which an exclusive property or privilege is claimed are
defined as
follows.
-35-
